Cognitive deficits occur in normal aging, and can be detected when performance is compared with that of young adult subjects, but age-related deficits are more selective and less severe than those in Alzheimer's disease (AD). The reasons for cognitive decline in aging are not known. The clinical diagnosis of probable AD rests upon the presence of deficits in memory and other cognitive domains, including attention, language, spatial abilities, abstract reasoning, and visual perception. Each patient's pattern of impaired and preserved function is likely to reflect the particular distribution of neuropathological changes in the brain. The goal of the proposed research is to related cognition in normal aging and AD to alterations in the functional magnetic resonance imaging (fMRI) signal within specific cerebral regions. We shall use novel high-speed fMRI methods to (a) obtain clues about the neural substrates of specific cognitive changes in aging and AD to alterations in the functional magnetic resonance imaging (fMRI) signal within specific cerebral regions. We shall use novel high-speed fMRI methods to (a) obtain clues about the neural substrates of specific cognitive changes in aging and AD, (b) document individual differences in those changes, and (c) identify neurophysiological markers that may signal very early AD. In order to achieve these goals, we shall perform 60 fMRI studies per year over a 5- year period in subjects with AD, older control subjects, nd young control subjects. We shall examine correlations between of fMRI signal and behavior in three cognitive domains that are vulnerable to the effects of aging and AD: long-term explicit memory, visual perception, and motor control.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005134-15
Application #
6267280
Study Section
Project Start
1998-04-15
Project End
1999-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
15
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Harvard University
Department
Type
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Dujardin, Simon; Bégard, Séverine; Caillierez, Raphaëlle et al. (2018) Different tau species lead to heterogeneous tau pathology propagation and misfolding. Acta Neuropathol Commun 6:132
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
DeVos, Sarah L; Corjuc, Bianca T; Commins, Caitlin et al. (2018) Tau reduction in the presence of amyloid-? prevents tau pathology and neuronal death in vivo. Brain 141:2194-2212
Lee, Christopher M; Jacobs, Heidi I L; Marquié, Marta et al. (2018) 18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. J Alzheimers Dis 62:1691-1702
Eftekharzadeh, Bahareh; Daigle, J Gavin; Kapinos, Larisa E et al. (2018) Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease. Neuron 99:925-940.e7
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Emerson, Sarah C; Waikar, Sushrut S; Fuentes, Claudio et al. (2018) Biomarker validation with an imperfect reference: Issues and bounds. Stat Methods Med Res 27:2933-2945
Petyuk, Vladislav A; Chang, Rui; Ramirez-Restrepo, Manuel et al. (2018) The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain 141:2721-2739

Showing the most recent 10 out of 966 publications